Trial Profile
A Prospective Study Investigating the Efficacy of an Interferon-Free Daclatasvir-Sofosbuvir-Ribavirin (DCV-SOF-RBV) Combination Regimen for the Treatment of HCV Genotype 3-Related Chronic Decompensated Liver Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C; Liver cirrhosis
- Focus Therapeutic Use
- 18 Jan 2018 New trial record